Table 3.
Prevalence of high-risk human papillomavirus genotypes according to the vaccine-targeted high-risk human papillomavirus genotypes
Total | |||||
---|---|---|---|---|---|
n = 595 | % | 95%CI | |||
Regarding HPV genotype | |||||
No high-riska | 160 | 26.89 | 23.24 | 30.54 | |
At least 1 high-risk | 435 | 73.11 | 69.46 | 76.76 | |
According to the vaccine-targeted high-risk HPV genotypes | |||||
No high-riska | 160 | 26.89 | 23.24 | 30.54 | |
Quadrivalent HPV non-vaccine-targeted high-risk HPV genotypesb | 229 | 38.49 | 34.49 | 42.48 | |
Quadrivalent HPV and nine-valent HPV non-vaccine-targeted high-risk HPV genotypesc | 107 | 17.98 | 14.81 | 21.15 | |
Additional five high-risk HPV genotypes present in the nine-valent HPV vaccined | 122 | 20.50 | 17.18 | 23.83 | |
Vaccine-targeted high-risk HPV genotypes (16 or 18) | 201 | 33.78 | 29.90 | 37.67 | |
Vaccine-targeted high-risk HPV genotypes (16 and 18) | 5 | 0.84 | 0.27 | 1.95 |
aNo high-risk. Classification human papillomavirus (HPV) types according to the World Health Organization International Agency for Research on Cancer (IARC) Monographs Working Group assessment of the carcinogenicity of different HPV types [25–27]
bAt least 1 of the quadrivalent HPV non-vaccine-targeted high-risk HPV genotypes (31 or 33 or 35 or 39 or 45 or 51 or 52 or 56 or 58 or 59 or 68)
cAt least 1 of the quadrivalent HPV and nine-valent HPV non-vaccine-targeted high-risk HPV genotypes (35 or 39 or 51 or 56 or 59 or 68)
dAt least 1 of the additional five high-risk HPV genotypes present in the nine-valent HPV vaccine (31 or 33 or 45 or 52 or 58)